Ernexa Therapeutics Inc. 8-K

What Happened
Ernexa Therapeutics Inc. (ERNA) announced on March 18, 2026 that Nasdaq’s Listing Qualifications Department notified the company its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, a violation of Nasdaq Listing Rule 5550(a)(2). Nasdaq determined the company is not eligible for the standard 180-calendar day compliance period because Ernexa completed a reverse stock split within the prior year under Nasdaq Listing Rule 5810(c)(3)(A)(iv). The company filed an 8‑K on March 20, 2026 and intends to request a hearing before the Nasdaq Hearing Panel.

Key Details

• Notice date: March 18, 2026; 8‑K filed March 20, 2026.
• Rule cited: Nasdaq Listing Rule 5550(a)(2) (minimum $1 bid price) and Nasdaq Listing Rule 5810(c)(3)(A)(iv) (reverse split exception).
• The company will request a hearing; the hearing request automatically stays any suspension or delisting pending the hearing.
• The Nasdaq Hearing Panel may grant an extension up to 180 days from the notice date to regain compliance, but no outcome is guaranteed.

Why It Matters
A failure to meet Nasdaq’s minimum bid price rule puts Ernexa’s continued listing at risk, which can reduce liquidity and make it harder for investors to buy or sell shares. Requesting a hearing pauses delisting actions while the company presents a plan to regain compliance; investors should monitor the hearing outcome and any updates on the company’s plan to raise the share price or otherwise satisfy listing requirements. The 8‑K also notes forward-looking statements and that there is no assurance a favorable Panel decision will be obtained.